已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study

贝里穆马布 医学 耐受性 不利影响 内科学 临床终点 痹症科 系统性红斑狼疮 红斑狼疮 子群分析 临床试验 疾病 免疫学 B细胞激活因子 抗体 置信区间 B细胞
作者
Yoshiya Tanaka,Paula Curtis,Kathleen DeRose,Regina Kurrasch,Kyoko Kinoshita,Rika Tanaka,Yumi Yamazaki,David A. Roth
出处
期刊:Modern Rheumatology [Informa]
卷期号:33 (1): 122-133 被引量:6
标识
DOI:10.1093/mr/roab125
摘要

ABSTRACT Objectives Evaluate long-term safety, tolerability, and efficacy of belimumab in Japanese patients with systemic lupus erythematosus (SLE). Methods This was a subgroup analysis of Japanese patients who completed studies BEL113750 or BEL112341 and were enrolled in a Phase 3, open-label extension study (BEL114333; NCT01597622). Eligible patients received intravenous belimumab 10 mg/kg every 28 days for ≤7 years. Primary endpoint: safety and tolerability. Secondary endpoints included SLE Responder Index (SRI)-4 response rate, SRI-4 components, severe SLE flare, and use of corticosteroids/other SLE-related treatments. Analyses were based on observed data from first belimumab dose received in either parent or current study through to study end. Results Of 71 Japanese patients enrolled, 69.0% completed the study. Overall, 98.6% patients had adverse events (AEs); 32.4% had serious AEs. The proportion of SRI-4 responders increased progressively (Year 1, Week 24: 40.9% [27/66]; Year 7, Week 48: 84.6% [11/13]) as did the proportion of Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index responders. The proportion of patients with no worsening in PGA (91.2–100.0%) and no new organ damage (92.6–100.0%) remained stable over time. Severe SLE flare was experienced by 11.3% (8/71) of patients. Corticosteroid and immunosuppressant use decreased over time. Conclusions Favourable safety profile and treatment responses with belimumab were maintained for ≤7 years in Japanese patients with SLE.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
隰宴发布了新的文献求助10
1秒前
1秒前
许xx完成签到 ,获得积分10
2秒前
curtain完成签到,获得积分10
4秒前
yyxxyy完成签到,获得积分10
4秒前
5秒前
curtain发布了新的文献求助10
6秒前
跳跃的谷雪完成签到 ,获得积分10
6秒前
zzzz完成签到 ,获得积分10
7秒前
yyxxyy发布了新的文献求助10
7秒前
霍普金斯医学院医学博士完成签到,获得积分10
8秒前
TillySss发布了新的文献求助10
9秒前
10秒前
11秒前
傲娇泥猴桃完成签到 ,获得积分10
14秒前
Biggest发布了新的文献求助10
16秒前
16秒前
TillySss完成签到,获得积分10
16秒前
饼夹菜完成签到,获得积分10
18秒前
20秒前
浮曳完成签到,获得积分10
20秒前
小枣完成签到 ,获得积分10
22秒前
sia完成签到 ,获得积分0
25秒前
fransiccarey完成签到,获得积分10
26秒前
wanci应助科研通管家采纳,获得10
29秒前
科研通AI2S应助科研通管家采纳,获得10
29秒前
脑洞疼应助科研通管家采纳,获得10
30秒前
科研通AI2S应助科研通管家采纳,获得10
30秒前
30秒前
Murphy完成签到 ,获得积分10
30秒前
30秒前
CipherSage应助轻松真采纳,获得10
41秒前
orixero应助一堃采纳,获得10
45秒前
45秒前
善学以致用应助影墨采纳,获得20
45秒前
jesusmanu完成签到,获得积分0
47秒前
47秒前
47秒前
深情安青应助小巧念露采纳,获得10
50秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3244606
求助须知:如何正确求助?哪些是违规求助? 2888340
关于积分的说明 8252567
捐赠科研通 2556793
什么是DOI,文献DOI怎么找? 1385287
科研通“疑难数据库(出版商)”最低求助积分说明 650094
邀请新用户注册赠送积分活动 626215